Abstract | BACKGROUND: METHODS: RESULTS: In the conventional premedication group, 21 patients had HSRs (32.3%); in 1 of these patients the HSR was considered to be severe (1.5%). In the short premedication group, 19 patients had HSRs (45.2%); in 6 of these patients the HSRs were considered to be severe (14.3%). The incidence of severe HSRs was significantly higher in the short premedication group than in the conventional premedication group (P = 0.027). In the modified premedication protocol study, HSR events were recorded in 14 patients (63.6%); 14 showed flushing, 2 had skin rash, and 1 had tachycardia. No severe HSRs were seen. CONCLUSIONS: The incidence of HSRs in the short premedication group tended to be higher than that in the conventional premedication group. The modified premedication protocol was found to be feasible for preventing paclitaxel-related HSR, but case accumulation is needed.
|
Authors | Shinji Sasada, Tomonori Hirashima, Yukiko Nakamura, Takayuki Takimoto, Mitsugi Furukawa, Masashi Kobayashi, Takashi Nitta, Kaoru Matsui, Ichiro Kawase |
Journal | International journal of clinical oncology
(Int J Clin Oncol)
Vol. 12
Issue 4
Pg. 274-8
(Aug 2007)
ISSN: 1341-9625 [Print] Japan |
PMID | 17701006
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- Bromides
- Calcium Compounds
- calcium bromide
- Diphenhydramine
- Paclitaxel
|
Topics |
- Adult
- Aged
- Antineoplastic Agents, Phytogenic
(adverse effects, therapeutic use)
- Bromides
(administration & dosage, therapeutic use)
- Calcium Compounds
(administration & dosage, therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy)
- Cohort Studies
- Diphenhydramine
(administration & dosage, therapeutic use)
- Drug Hypersensitivity
(etiology, prevention & control)
- Female
- Humans
- Injections, Intravenous
- Lung Neoplasms
(drug therapy)
- Male
- Middle Aged
- Paclitaxel
(adverse effects, therapeutic use)
- Premedication
- Retrospective Studies
|